A clinical trial has demonstrated that Regeneron’s brand of dupilumab (Dupixent®) substantially decreased urticaria and itch activity compared to a placebo.
Additionally, a higher percentage of Dupixent-treated patients attained well-controlled disease status.
The study, coded LIBERTY-CUPID recruited qualifying participants who were of ages 6 years and above.
One group received Dupixent together with standard of care antihistamines, while the comparator group received a placebo with the same antihistamines.
In approximately six months, patients treated with Dupixent experienced an 8.64-point reduction in itch severity, compared to 6.10 points in the placebo group.
Similarly, Dupixent reduced the urticaria activity score by 15.86 points, compared to 11.21 points with placebo, demonstrating superior efficacy.
Dupilumab is a monoclonal antibody whose mode of action involves inhibition of interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways.
READ ALSO: Pfizer’s RSV vaccine gets FDA nod for adults with increased risk of disease
This results in preventing type 2 inflammation and can therefore be used in the management of patients with chronic spontaneous urticaria (CSU), atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other inflammatory conditions.
“These data confirm results seen in the previous Study A and reinforce the potential of Dupixent to significantly alleviate symptoms for patients, helping them to better control this challenging disease,” stated Thomas B. Casale, M.D., Professor, University of South Florida, USA.
Regeneron’s Dupixent has been approved for CSU management in the United Arab Emirates (UAE) as well as Japan. In another 58 countries, the biologic has been authorized for use in the treatment of chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and more.
The results from the LIBERTY-CUPID Study C trial are being shared at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts.
Did you find this insightful? Subscribe for more.
Writer
APR Team
African Pharmaceutical Review team dedicated to providing the latest news, insights and developments from the pharma, biotech and medtech industries.
.jpg)
.jpg)
.jpg)